Xconomy | Boston - Business + Technology in the Exponential Economy

Kolltan Adds $5M to Series A

Kolltan Pharmaceuticals, the New Haven, CT-based developer of cancer drugs, said today it has raised an additional $5 million as part of its Series A financing, bringing the total round to $40 million. Kolltan, a spinout from the Yale University lab of Joseph Schlessinger, announced its initial $35 million financing in January. Investors in the Series A financing include Purdue Pharma, HBM BioCapital, the Pritzker/Vlock family, and other private life sciences investors.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: